Important Notice for Capricor Therapeutics, Inc. Investors
The Gross Law Firm is reaching out to shareholders regarding a class action lawsuit involving Capricor Therapeutics, Inc. (NASDAQ: CAPR). Investors who acquired shares during the specified class period are encouraged to connect with the firm to discuss their potential involvement in the lawsuit. It's essential to understand that you do not need to be appointed as a lead plaintiff to participate in any potential recovery.
Details of the Class Action
The class period for this action spans from October 9, 2024, to July 10, 2025. During this time, the allegations include that the company misled investors about the efficacy of its lead drug candidate, deramiocel, intended for treating cardiomyopathy linked to Duchenne muscular dystrophy (DMD). The complaint indicates that while the company touted its ability to obtain approval from the U.S. Food and Drug Administration (FDA) for the drug, there were substantial omissions regarding adverse information related to the four-year safety and efficacy data from the Phase 2 HOPE-2 trial. On July 11, 2025, Capricor announced an FDA Complete Response Letter, stating that its application did not meet the necessary requirements for substantial evidence of effectiveness, resulting in a significant drop in the stock price.
Significant Decline in Stock Price
Investors should be aware that following the negative announcement from the FDA, Capricor's stock plummeted from $11.40 on July 10, 2025, to $7.64 on July 11, 2025. This sharp decline represents a profound concern for shareholders and highlights the necessity of taking action regarding the potential recovery for losses incurred during this period.
Deadline for Participation
The deadline for shareholders to register in connection with this class action lawsuit is September 15, 2025. If you purchased shares during the timeframe mentioned, it would be prudent to register your information to ensure you are included in any proceedings. It's important to act promptly as the deadline approaches.
Next Steps for Shareholders
After registering as a shareholder who bought shares during the specified dates, you will gain access to portfolio monitoring software. This tool keeps you updated with the case's status and progression throughout its lifecycle. There is no cost associated with registering or participating, making it a beneficial step for all affected shareholders.
Why Choose The Gross Law Firm?
The Gross Law Firm is distinguished in the area of class action lawsuits, with a strong focus on advocating for the rights of investors. The firm is dedicated to holding companies accountable for deceptive practices and ensuring ethical business operations. Their commitment encompasses seeking restitution for investors who have experienced losses stemming from misleading or false statements made by companies.
For more information or assistance, reach out to The Gross Law Firm using the following contact details:
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the class period for the Capricor Therapeutics lawsuit?
The class period for the lawsuit extends from October 9, 2024, to July 10, 2025.
What are the allegations against Capricor Therapeutics?
The allegations state that the company misrepresented its lead drug candidate, deramiocel, omitting crucial safety information while promoting its potential to obtain FDA approval.
How has the stock price of CAPR changed recently?
Following the FDA’s Complete Response Letter, the stock dropped significantly, from $11.40 per share to $7.64 per share.
What is the deadline to register for this class action?
The deadline to register is September 15, 2025, and shareholders are urged to register promptly.
Why should I choose The Gross Law Firm?
The Gross Law Firm is renowned for protecting investor rights and advocating against fraudulent practices, ensuring that companies are held accountable for their actions.
